全文获取类型
收费全文 | 3281616篇 |
免费 | 276935篇 |
国内免费 | 14143篇 |
专业分类
耳鼻咽喉 | 44930篇 |
儿科学 | 100430篇 |
妇产科学 | 83901篇 |
基础医学 | 523282篇 |
口腔科学 | 88749篇 |
临床医学 | 294755篇 |
内科学 | 572626篇 |
皮肤病学 | 86824篇 |
神经病学 | 285331篇 |
特种医学 | 129833篇 |
外国民族医学 | 207篇 |
外科学 | 512707篇 |
综合类 | 103674篇 |
现状与发展 | 24篇 |
一般理论 | 2421篇 |
预防医学 | 278502篇 |
眼科学 | 75446篇 |
药学 | 226355篇 |
25篇 | |
中国医学 | 9383篇 |
肿瘤学 | 153289篇 |
出版年
2021年 | 56009篇 |
2020年 | 35699篇 |
2019年 | 59003篇 |
2018年 | 71960篇 |
2017年 | 54815篇 |
2016年 | 60541篇 |
2015年 | 74804篇 |
2014年 | 109520篇 |
2013年 | 175173篇 |
2012年 | 96116篇 |
2011年 | 95623篇 |
2010年 | 117740篇 |
2009年 | 122006篇 |
2008年 | 81380篇 |
2007年 | 84781篇 |
2006年 | 95431篇 |
2005年 | 90998篇 |
2004年 | 92688篇 |
2003年 | 83221篇 |
2002年 | 72134篇 |
2001年 | 84716篇 |
2000年 | 76747篇 |
1999年 | 80643篇 |
1998年 | 63766篇 |
1997年 | 62057篇 |
1996年 | 59698篇 |
1995年 | 55173篇 |
1994年 | 49504篇 |
1993年 | 46273篇 |
1992年 | 57693篇 |
1991年 | 54880篇 |
1990年 | 52073篇 |
1989年 | 51667篇 |
1988年 | 48439篇 |
1987年 | 47370篇 |
1986年 | 45164篇 |
1985年 | 45766篇 |
1984年 | 43836篇 |
1983年 | 40471篇 |
1982年 | 40512篇 |
1981年 | 38344篇 |
1980年 | 36240篇 |
1979年 | 37047篇 |
1978年 | 33685篇 |
1977年 | 30959篇 |
1976年 | 28175篇 |
1975年 | 26670篇 |
1974年 | 27807篇 |
1973年 | 26713篇 |
1972年 | 25150篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
981.
D. Sforza G. Iaria L. Petagna A. Parente A. Anselmo F. Sergi S. Marzio F. Corrado S. Telli T.M. Manzia G. Tisone 《Transplantation proceedings》2019,51(1):140-142
Background
One daily dose of tacrolimus (QDT) improves adherence in kidney transplant (KT) recipients. A switch from twice-daily tacrolimus (BDT) to QDT showed similar efficacy and safety.Methods
The aim of our study was to demonstrate the long-term efficacy and safety of switching from BDT to QDT in KT recipients. Preliminary results have already been published. Forty-one patients (34 men and 7 women), mean age at KT of 43.9 ± 12.7 years, underwent a 1:1 dose switch from BDT to QDT; the mean time from KT to switch was 36.6 ± 16.1 months. In our study population, 4 patients received a living donor KT and 2 received a second allograft.Results
The mean follow-up was 86.8 ± 13 months from the switch and 126.2 ± 22.3 months from KT. Graft and patient survival rates were 90.2% and 95.1%, respectively. All patients maintained stable renal function during follow-up. During the first 3 months after the switch we observed a significant decrease in tacrolimus blood level (P = .0001). No significant differences were observed regarding tacrolimus dose before and after QDT introduction (P = not significant [NS]). Fourteen patients who stopped steroids under BDT treatment and 16 patients who stopped steroids after the switch are currently steroid-free.Conclusion
Our study showed safety and efficacy in switching from BDT to QDT. After early (<1 year) dose adjustment, tacrolimus blood levels remained stable throughout follow-up. Moreover, QDT represented a valid alternative for patients showing steroid side effects. 相似文献982.
A high resolution depth attenuation product (Kdhires) was developed using MODIS 500 m and 250 m spectral bands. The Kdhires was compared with Wang’s operational Kd for the Chesapeake Bay. Minimal differences were observed between the two methods, with greatest deviation occurring in areas of high turbidity in the tributaries. After tuning the new Kdhires, the mean absolute error and bias between the two algorithms was 0.22 m?1 and 0.026 m?1, indicating good agreement. Higher spatial resolution provides for improved retrievals along the coast and into the narrow sections of the tributaries, coinciding with areas of concern to estuarine health and coastal management applications. 相似文献
983.
984.
Anand Dayama Nikolaos Tsilimparis Stephen Kolakowski Nathaniel M. Matolo Misty D. Humphries 《Journal of vascular surgery》2019,69(1):156-163.e1
Background
Chronic limb-threatening ischemia (CLTI), defined as ischemic rest pain or tissue loss secondary to arterial insufficiency, is caused by multilevel arterial disease with frequent, severe infrageniculate disease. The rise in CLTI is in part the result of increasing worldwide prevalence of diabetes, renal insufficiency, and advanced aging of the population. The aim of this study was to compare a bypass-first with an endovascular-first revascularization strategy in patients with CLTI due to infrageniculate arterial disease.Methods
We reviewed the American College of Surgeons National Surgical Quality Improvement Program targeted lower extremity revascularization database from 2012 to 2015 to identify patients with CLTI and isolated infrageniculate arterial disease who underwent primary infrageniculate bypass or endovascular intervention. We excluded patients with a history of ipsilateral revascularization and proximal interventions. The end points were major adverse limb event (MALE), major adverse cardiovascular event (MACE), amputation at 30 days, reintervention, patency, and mortality. Multivariable logistic regression was used to determine the association of a bypass-first or an endovascular-first intervention with outcomes.Results
There were 1355 CLTI patients undergoing first-time revascularization to the infrageniculate arteries (821 endovascular-first revascularizations and 534 bypass-first revascularizations) identified. There was no significant difference in adjusted rate of 30-day MALE in the bypass-first vs endovascular-first revascularization cohort (9% vs 11.2%; odds ratio [OR], 0.73; 95% confidence interval [CI], 0.50-1.08). However, the incidence of transtibial or proximal amputation was lower in the bypass-first cohort (4.3% vs 7.4%; OR, 0.60; CI, 0.36-0.98). Patients with bypass-first revascularization had higher wound complication rates (9.7% vs 3.7%; OR, 2.75; CI, 1.71-4.42) compared with patients in the endovascular-first cohort. Compared with the endovascular-first cohort, the incidence of 30-day MACE was significantly higher in bypass-first patients (6.9% vs 2.6%; adjusted OR, 3.88; CI, 2.18-6.88), and 30-day mortality rates were 3.23% vs 1.8% (adjusted OR, 2.77; CI, 1.26-6.11). There was no difference in 30-day untreated loss of patency, reintervention of treated arterial segment, readmissions, and reoperations between the two cohorts. In subgroup analysis after exclusion of dialysis patients, there was also no significant difference in MALE or amputation between the bypass-first and endovascular-first cohorts.Conclusions
CLTI patients with isolated infrageniculate arterial disease treated by a bypass-first approach have a significantly lower 30-day amputation. However, this benefit was not observed when dialysis patients were excluded. The bypass-first cohort had a higher incidence of MACE compared with an endovascular-first strategy. These results reaffirm the need for randomized controlled trials, such as the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL-2) trial and Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI), to provide level 1 evidence for the role of endovascular-first vs bypass-first revascularization strategies in the treatment of this population of challenging patients. 相似文献985.
986.
S. Natoli V. Oliveira P. Calabresi L. F. Maia A. Pisani 《European journal of neurology》2020,27(9):1764-1773
The current coronavirus disease (COVID‐19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS‐CoV‐2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus (CoV) from a translational perspective. Animal models of SARS and Middle East respiratory syndrome, caused by structurally similar CoVs during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by CoVs and the potential for central nervous system spread of SARS‐CoV‐2. One key finding that may unify these pathogens is that all require angiotensin‐converting enzyme 2 as a cell entry receptor. The CoV spike glycoprotein, by which SARS‐CoV‐2 binds to cell membranes, binds angiotensin‐converting enzyme 2 with a higher affinity compared with SARS‐CoV. The expression of this receptor in neurons and endothelial cells hints that SARS‐CoV‐2 may have higher neuroinvasive potential compared with previous CoVs. However, it remains to be determined how such invasiveness might contribute to respiratory failure or cause direct neurological damage. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune‐mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune‐mediated pathogenicity in the short and medium term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous CoV infections and discuss their potential relevance to COVID‐19. 相似文献
987.
Leah H. Cobb Emily M. McCabe Lauren B. Priddy 《Journal of orthopaedic research》2020,38(10):2091-2103
Osteomyelitis, or the infection of the bone, presents a major complication in orthopedics and may lead to prolonged hospital visits, implant failure, and in more extreme cases, amputation of affected limbs. Typical treatment for this disease involves surgical debridement followed by long-term, systemic antibiotic administration, which contributes to the development of antibiotic-resistant bacteria and has limited ability to eradicate challenging biofilm-forming pathogens including Staphylococcus aureus—the most common cause of osteomyelitis. Local delivery of high doses of antibiotics via traditional bone cement can reduce systemic side effects of an antibiotic. Nonetheless, growing concerns over burst release (then subtherapeutic dose) of antibiotics, along with microbial colonization of the nondegradable cement biomaterial, further exacerbate antibiotic resistance and highlight the need to engineer alternative antimicrobial therapeutics and local delivery vehicles with increased efficacy against, in particular, biofilm-forming, antibiotic-resistant bacteria. Furthermore, limited guidance exists regarding both standardized formulation protocols and validated assays to predict efficacy of a therapeutic against multiple strains of bacteria. Ideally, antimicrobial strategies would be highly specific while exhibiting a broad spectrum of bactericidal activity. With a focus on S. aureus infection, this review addresses the efficacy of novel therapeutics and local delivery vehicles, as alternatives to the traditional antibiotic regimens. The aim of this review is to discuss these components with regards to long bone osteomyelitis and to encourage positive directions for future research efforts. 相似文献
988.
989.